Novartis Ag (NVS) EBITDA Margin Growth (3y) (2017 - 2024)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBITDA Margin Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
2,500.00 |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-91.00 |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
395.00 |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-4,555.00 |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-53.00 |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
1,031.00 |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-9,003.00 |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
546.00 |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2024 |
983.00 |
| Dec 31, 2023 |
-12,932.00 |
| Jun 30, 2023 |
-24.00 |
| Mar 31, 2023 |
11,729.00 |
| Mar 31, 2022 |
3,714.00 |
| Dec 31, 2021 |
-10,303.00 |
| Sep 30, 2021 |
5,430.00 |
| Jun 30, 2021 |
1,334.00 |
| Mar 31, 2021 |
-8,189.00 |
| Dec 31, 2020 |
273.00 |
| Sep 30, 2020 |
-3,716.00 |
| Jun 30, 2020 |
-115,937.00 |
| Mar 31, 2019 |
-6,690.00 |
| Dec 31, 2018 |
-22,836.00 |
| Sep 30, 2018 |
-12,719.00 |
| Mar 31, 2018 |
-3,374.00 |
| Dec 31, 2017 |
-26,855.00 |
| Sep 30, 2017 |
-20,655.00 |
